This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant

MUNICH, May 21, 2012 /PRNewswire/ --

SERVE-HF, the largest study to investigate if treatment of predominant central sleep apnea (CSA) improves survival and outcomes of patients with stable heart failure, has enrolled its 1,000 th participant. The study, sponsored by ResMed Ltd., is the largest of its kind. This milestone brings the SERVE-HF study, which began in 2008, one step closer to its target of approximately 1,250 participants.

Principal investigator Prof. Martin Cowie, of the Royal Brompton Hospital in London said, "SERVE-HF is the world's largest study for any aspect of sleep-disordered breathing [SDB], and it has involved significant collaboration among sleep physicians, respiratory physicians and cardiologists across Europe."

Co-principal investigator, Prof. Helmut Teschler, Medical Director at the Department of Pneumology, Ruhrland Clinic, Essen, added, "This study is so important because SDB in heart failure patients is a very common occurrence, particularly in men.  Given that at least 50% of men with heart failure also suffer from moderate to severe SDB, treatment of SDB could be vital to improving heart failure outcomes in the future."

Patients with heart failure may have an abnormal waxing and waning breathing pattern called Cheyne-Stokes respiration (CSR) with CSA.  Previous studies have demonstrated that such patients have a poor quality of life as well as increased mortality, but that they may do better and live longer if they are treated with assisted ventilation during sleep.

The SERVE-HF study hopes to provide more conclusive evidence of the health benefits of treating SDB in heart failure patients, and on a much larger scale.  The study is being conducted at more than 80 sites in Germany, France, the UK, Norway, Sweden, Denmark, Finland, Australia and the Czech Republic.

The primary goal of the study is to determine whether managing CSR-CSA with ResMed's proprietary adaptive servo-ventilation technology (found in its AutoSet CS™ and VPAP™ Adapt devices) increases survival rates and decreases the burden of hospitalizations in this patient population.  Adaptive servo-ventilation is an intelligent method of non-invasive ventilation that continuously monitors and stabilizes the breathing patterns of individuals with SDB throughout the night.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,010.68 -115.44 -0.64%
S&P 500 2,107.39 -13.40 -0.63%
NASDAQ 5,070.0260 -27.95 -0.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs